Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMNSH0V)

Drug Name
L-741604 Drug Info
Synonyms
L-741604; CHEMBL296161; SCHEMBL6943364; IGNXHSPBUUSUHB-UHFFFAOYSA-N; BDBM50060426; L010084; N,N-dimethyl-2-[5-(1,2,4-triazol-4-yl)-1H-indol-3-yl]ethylamine; Dimethyl-[2-(5-[1,2,4]triazol-4-yl-1H-indol-3-yl)-ethyl]-amine
Cross-matching ID
PubChem CID
9881526
TTD Drug ID
DMNSH0V

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Download the Complete Related Drug List
Drug(s) Targeting 5-HT 1D receptor (HTR1D)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Metergolin DMJFP6G Hyperprolactinaemia 5A60.1 Approved [2]
Eletriptan DMW649X Migraine 8A80 Approved [3]
Zolmitriptan DM1IB4Q Migraine 8A80 Approved [3]
Frovatriptan DM7RE8P Migraine 8A80 Approved [3]
Sumatriptan DMVYXR8 Cluster headache 8A81.0 Approved [4]
Rizatriptan DMDJMA3 Migraine 8A80 Approved [5]
Almogran DM7I64Z Migraine 8A80 Approved [6]
Neu-P11 DMIQDFW Alzheimer disease 8A20 Phase 2 [7]
FKB01MD DM2O7NM N. A. N. A. Phase 2 [8]
NXN-188 DMMBAIH Migraine 8A80 Phase 2 [9]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas
Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
5-HT 1D receptor (HTR1D) TT6MSOK 5HT1D_HUMAN Inhibitor [1]

References

1 3-(Piperazinylpropyl)indoles: selective, orally bioavailable h5-HT1D receptor agonists as potential antimigraine agents. J Med Chem. 1999 Feb 25;42(4):691-705.
2 Primary structure and functional characterization of a human 5-HT1D-type serotonin receptor. Mol Pharmacol. 1991 Aug;40(2):143-8.
3 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
4 Irritable bowel syndrome: new agents targeting serotonin receptor subtypes. Drugs. 2001;61(3):317-32.
5 An introduction to migraine: from ancient treatment to functional pharmacology and antimigraine therapy. Proc West Pharmacol Soc. 2002;45:199-210.
6 Efficacy and tolerability of subcutaneous almotriptan for the treatment of acute migraine: a randomized, double-blind, parallel-group, dose-finding study. Clin Ther. 2001 Nov;23(11):1867-75.
7 Clinical pipeline report, company report or official report of Neurim Pharmaceuticals.
8 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
9 Company report (NeurAxon)